Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03101839 | Phase I Dose-Escalation Study of AZD4785 in Patients With Advanced Solid Tumours | PHASE1 | COMPLETED | 28 | — | — | May 15, 2017 | Jan 8, 2019 | Oct 4, 2019 | 5 | United States, United Kingdom |
Determined through the evaluation of dose-limiting toxicity (DLT), adverse events, clinical laboratory test results, clinical evaluation and patient reported symptoms
| Arm | Type | Description |
|---|---|---|
| AZD4785 | EXPERIMENTAL | This is a single-arm study in which all patients will receive AZD4785 by IV infusion. Patients will continue to receive treatment with AZD4785 until disease progression, intolerable toxicity, or discontinuation criteria are met. |
| Name | Type | Description |
|---|---|---|
| AZD4785 | DRUG | KRAS Antisense Oligonucleotide |
Inclusion Criteria Part A Dose Escalation: Patients must have histological or cytological confirmation of a solid tumour known to harbour KRAS mutations (e.g., NSCLC, mCRC, pancreatic or cholangiocarcinoma), and have progressed despite standard therapy(ies), or are intolerant to standard therapy(ie...